Safety of anticoagulation in elective colonoscopy

Phase 4

• Conditions: Thromboembolism; Peri-procedural care; Elective colonoscopy; Blood - Other blood disorders; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

• Registration Number: ACTRN12621001644853
• Lead Sponsor: Dr Nicholas Tutticci

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-11-30
• Last Update Posted: 6 December 2021

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1) Patients undergoing elective colonoscopy
2) Chronically anti-coagulated with DOACs (Apixaban/Dabigatran/Rivaroxaban)

Exclusion Criteria

1) Individual characteristics:
oConcurrent antiplatelet therapy prescribed
oDischarge location distance from the hospital of greater than 100 kilometres
oIndividuals unable to give consent
oPatients with renal impairment (defined as eGFR <45)

2) Continuation of anticoagulation is not advised:
oPrior peri-procedural bleeding requiring anticoagulation cessation/intervention/hospitalisation

3) Interruption to anticoagulation not recommended:
oThromboembolic event in the preceding 3 months
oActive malignancy

4) Procedure planned to be performed by alternative clinician not participating in the study

5) Endoscopic factors:
oEmergency procedure
oConcurrent endoscopy being performed on same day
oPlanned therapeutic procedure (i.e. large polypectomy/endo-mucosal resection/endoscopic submucosa dissection/dilatation)
oExpected high burden of polyps (i.e. known polyposis syndrome not yet completed clearance colonoscopy)

Study & Design

• Study Type: Interventional
• Study Design: Not specified